SavedAdd your journal

Journals / Turkish Thoracic Journal / 2018 / Cilt: 19 - Sayı: 1

A Case Report of Secondary Simultaneous Bilateral Pneumothorax Due to Pazopanib Treatment

BURÇİN ÇELİK
Zeynep Pelin SÜRÜCÜ
Volkan YILMAZ
Hale KEFELİ ÇELİK
Pages
49–51
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thepatient being presented in this article underwent surgery for soft tissue sarcoma, postoperatively received pazopanib (Votrient® 400 mg,oral, Glaxo Group Ltd, Brentford, UK) treatment due to widespread bilateral lung metastases, and developed synchronous spontaneouspneumothorax.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Secondary spontaneous pneumothorax almost always develops secondary to an underlying lung disease.
📊
Key Findings & Data:The rate of pneumothorax that is caused by pazopanib is about 14% in the literature.
💡
Conclusion & Impact:Thepatient being presented in this article underwent surgery for soft tissue sarcoma, postoperatively received pazopanib (Votrient® 400 mg,oral, Glaxo Group Ltd, Brentford, UK) treatment due to widespread bilateral lung metastases, and developed synchronous spontaneouspneumothorax.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Secondary spontaneous pneumothorax almost always develops secondary to an underlying lung disease. A pneumothorax secondaryto a malignancy is very rare, and is observed most frequently in soft tissue sarcomas. Pazopanib, a tyrosine kinase inhibitor, is used inmetastatic soft tissue sarcomas treatment. The rate of pneumothorax that is caused by pazopanib is about 14% in the literature. Thepatient being presented in this article underwent surgery for soft tissue sarcoma, postoperatively received pazopanib (Votrient® 400 mg,oral, Glaxo Group Ltd, Brentford, UK) treatment due to widespread bilateral lung metastases, and developed synchronous spontaneouspneumothorax.

🔖

Cite This Article

ÇELİK, B., SÜRÜCÜ, Z. P., YILMAZ, V., ÇELİK, H. K. (2018). A Case Report of Secondary Simultaneous Bilateral Pneumothorax Due to Pazopanib Treatment. Turkish Thoracic Journal, Cilt: 19 - Sayı: 1, 49–51. https://ajindex.com/articles/418047

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Karamustafaoğlu A. Pnömotoraks ve pnömomediastinum. In: Göğüs Cerrahisi ''Kırmızı Kitap''. Yüksel M, Balcı AE, eds. Nobel Tıp Kitapevleri Tic. Ltd. Şti., İstanbul. 2015;555-562. Melton LJ 3rd, Hepper NG, Offord KP. Incidence of spontaneous pneumothorax in Olmsted County, Minnesota: 1950 to 1974. Am Rev Respir Dis 1979;29:1379-82.
  2. Vencevicius V, Cicenas S. Spontaneous pneumothorax as a first sign of pulmonary carcinoma. World J Surg Oncol 2009;7:57. [CrossRef] Verschorr AJ, Gelderblom H. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma terated with pazopanib: a single reference centre case series. Clin Sarcoma Res 2014;4:14. [CrossRef] Nakano K, Inagaki L, Tomomatsu J, et al. Incidence of pneumo- thorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment. Clin Oncol 2014;26: 357. [CrossRef] van der Graaf WT, Blay JY, Chawla SP, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo- controlled phase 3 trial. Lancet 2012;379:1879-86. [CrossRef] Srinivas S, Varadhachary G. Spontaneous pneumothorax in ma- lignancy: a case report and review of the literature. Ann Oncol 2000;11:887-9. [CrossRef]